- AU$47.27m
- AU$42.83m
- AU$32.33m
Australia Stock Exchange release from CYCLOPHARM : Initial Director's Interest Notice
Brief: Cyclopharm Sees H1 Revenue To Be About $8.1 MLN, up 45%
Australia's Cyclopharm sees best day in nearly four months on revenue outlook
Australia Stock Exchange release from CYCLOPHARM : CYC First Half Trading Update
Australia Stock Exchange release from CYCLOPHARM : PRE_NR Ends: 08:31:58
Australia's Cyclopharm sees worst day ever on FDA response to drug application
Brief: Cyclopharm Says U.S. FDA Unable To Approve NDA For Technegastm In Present Form
Australia Stock Exchange release from CYCLOPHARM : Cyclopharm USFDA Update
Australia Stock Exchange release from CYCLOPHARM : PRE_NR Ends: 08:33:15
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MUFG
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MS
Australia Stock Exchange release from CYCLOPHARM : Becoming a substantial holder from MUFG
Australia Stock Exchange release from CYCLOPHARM : Becoming a substantial holder from MS
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MUFG
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MS
Australia Stock Exchange release from CYCLOPHARM : Becoming a substantial holder from MUFG
Australia Stock Exchange release from CYCLOPHARM : Becoming a substantial holder from MS
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MUFG
Australia Stock Exchange release from CYCLOPHARM : Ceasing to be a substantial holder from MS